Sonoma Pharmaceuticals' Microdox® shows potential in managing UTIs in children with bladder dysfunction, per a study in Neurourology and Urodynamics.
Sonoma Pharmaceuticals reports a study published in Neurourology and Urodynamics, showing potential for Microdox®, a super-oxidized solution based on its patented Microcyn technology, in managing urinary tract infections (UTIs) in children with neurogenic or non-neurogenic bladder dysfunction. Microdox is licensed in Australia and New Zealand for the prevention and treatment of UTIs.
April 04, 2024
5 Articles